文献速递皮肤肿瘤

低剂量长期卡培他滨治疗难治性区域癌化:回顾性队列研究

Low-dose long-term capecitabine for refractory field cancerization: A retrospective cohort study.
PubMed 文献 · J Am Acad Dermatol · 2026-06-27

本研究回顾性分析20例局部治疗难治的皮肤区域癌化患者,接受长期低剂量卡培他滨治疗,平均治疗20.8个月。75%受访患者认为皮肤病变至少中度改善,83.3%偏好卡培他滨而非其他治疗,10%因毒性停药。

要点

  • 低剂量长期卡培他滨可减少区域癌化患者的角质形成细胞癌手术量。
  • 第2年手术量显著下降73%,但第1、3年下降无统计学意义。
  • 多数患者对卡培他滨满意且耐受良好,10%因毒性停药。

核心结论

  • 卡培他滨可减少角质形成细胞癌的发生,且长期耐受性良好。

研究设计与样本

  • 单中心回顾性队列和调查研究,纳入20例接受卡培他滨治疗的皮肤区域癌化患者。
  • 采用Wilcoxon配对符号秩检验比较治疗前与治疗后第1、2、3年的年角质形成细胞癌手术量。

主要发现

  • 20例患者治疗时间平均20.8个月(范围0.8-57.5),其间平均治疗假期8.0个月(范围0-33.1)。
  • 2例(10%)因毒性停止治疗;17例受邀调查中12例回复(回复率70.6%),75.0%认为卡培他滨至少中度改善皮肤病变,83.3%偏好卡培他滨而非其他治疗。

临床怎么用

  • 对于局部治疗难治的皮肤区域癌化患者,可考虑长期低剂量卡培他滨治疗,但需监测毒性。
  • 治疗获益可能在第2年更明显,需个体化评估疗程。

局限性

  • 回顾性设计,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical-refractory cutaneous field cancerization is challenging to manage and distressing to patients. OBJECTIVE: Evaluate the efficacy, toxicity, and patient satisfaction of long-term, low-dose capecitabine for field cancerization. METHODS: A retrospective cohort and survey study was performed at a single institution of patients treated with capecitabine for cutaneous field cancerization. Wilcoxon matched-pairs signed-rank test was used to compare annual keratinocyte carcinoma surgeries pre- and post-treatment at years 1, 2, and 3. RESULTS: Twenty patients were treated over 20.8 months (range 0.8-57.5) including 8.0 months (0-33.1) of intervening treatment holidays. Mean keratinocyte carcinoma surgeries decreased in all years of treatment compared to the year before treatment (1-year (n = 18): 3.89 precapecitabine to 2.94, 24% reduction, P = .29; 2-year (n = 11): 3.46 precapecitabine to 0.93, 73% reduction, P = .02; 3-year (n = 5): 3.00 precapecitabine to 2.20, 27% reduction, P > .99). Two patients (10%) discontinued therapy due to toxicity. Of 17 patients offered the survey, 12 responded (response rate 70.6%). A majority (75.0%) felt capecitabine improved their skin lesions at least moderately and 83.3% preferred capecitabine to alternative treatments. LIMITATIONS: Retrospective design, small sample size. CONCLUSION: Capecitabine reduces incident keratinocyte carcinomas and is well-tolerated long-term.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Neff H, Mortelliti C, Solomon B, et al. Low-dose long-term capecitabine for refractory field cancerization: A retrospective cohort study. J Am Acad Dermatol. 2026. PMID: 42364769. doi:10.1016/j.jaad.2026.06.111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。